
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hydrogen Peroxide
Therapeutic Area : Dental and Oral Health
Study Phase : Phase III
Sponsor : BMG Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hydrogen Peroxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Periodontitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 25, 2020
Lead Product(s) : Hydrogen Peroxide
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Sponsor : BMG Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hydrogen Peroxide
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase III
Sponsor : BMG Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hydrogen Peroxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Wound Healing.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 18, 2020
Lead Product(s) : Hydrogen Peroxide
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Sponsor : BMG Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Polaprezinc
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Azienda Farmaceutica Italiana
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Zinc L-Carnosine Mouth Rinse
Details : Zinc L-Carnosine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
June 16, 2020
Lead Product(s) : Polaprezinc
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Azienda Farmaceutica Italiana
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Regen Lab
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Hyaluronic Acid and Platelet-rich Plasma Combination in Knee Osteoarthritis
Details : Hyaluronic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 07, 2017
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Regen Lab
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tobramycin
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis
Details : Tobramycin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cystic Fibrosis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 31, 2012
Lead Product(s) : Tobramycin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
